

WyoBlue Advantage is informing providers of upcoming changes for medical benefit drugs

Changes to preferred drug designations for Denosumab products starting October 15, 2026, and again on December 1, 2026

Prior authorization and site-of-care requirements currently apply to these denosumab products. Review the posted Part B Drug List to confirm the preferred product(s) and applicable effective dates.

HCPC Code Updates Effective October 1, 2026

- Avlayah (Tividenofusp alfa-eknm) J1757
- Loargys (egzilarginase-nbln) J1818

Drugs Newly Requiring Prior Authorization Effective October 15, 2026

- Ponlimsi (denosumab-adet) Q5173
- Zanzastro (zilganerssen) J3590
- Isembyld™IV (apitegromab-mstn) J3590
- Fayuvi™IV (rebisufligene etisparvovec-hopf) J3590
- Decnupaz™ (pivekimab sunirine-pvzy) J9999
- Filkri™ (filgrastim-laha) Q5172
- Navitrux™ (fosaprepitant) J3490
- Posfrea™ (palonosetron) J2468
- Sarclisa Escena™ (isatuximab-irfc) J9999
- Revtorpyk™ (gedatolisib) J9999
- Pasatru (garetosmab-grts) J3590

Drugs Newly Requiring Prior Authorization Effective December 1, 2026

- Osenvelt (denosumab-bmwo) Q5157
- Vykoura (leucovorin calcium) J0644
- Tudriqev (vusolimogene oderparepvec-wtpg) J3590
- Yondelis® (Trabectedin) J9362
- Favlyxa (Fluorouracil) J9191
- Avopef (Etoposide) J9186
- Aphexda (motixafortide) J2277
- Evdi (Trabectedin) J9999

Prior Authorization Submission Methods

Prior approval must be submitted through one of the following methods:

- Electronically: Use the Symphony Prior Authorization Portal, available within the Availity Essentials portal.
- Phone call: (844) 965-5080
- Paper form/Fax: Download the form from the WyoBlue Advantage website and fax it to (877) 369-3365.